121 results about "Salicylanilides" patented technology

This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and / or niclosamide analogues when orally administered in conjunction with a peptide pharmaceutical (e.g., a class A amphipathic helical peptide as described herein) significantly increases the bioavailability of that peptide. Methods of peptide delivery using such “delivery agents” and pharmaceutical formulations are provided.

A composition prepared for treating animals suffering from parasites which parasites are known to be susceptible to at least one of the avermectins, milbemycins or salicylanilides, comprises for example ivermectin in an amount of from 0.1 to 10%(w / v), a solvent selected from the group consisting of glycerol formal, propylene glycol, polyethylene glycol and combinations thereof, and a salicylanilide such as closantel in a required dosage amount for the animal to be treated, typically about 2.5 mg / kg live weight of the animal to be treated, a polymeric species selected from the group consisting of polyvinylpyrrolidone and polyoxypropylene / polyoxyethylene block copolymers, the said polymeric species improving the bioavailability of closantel to the extend that blood plasma levels of the said compound greater than about 20 ppm over period of treatment are achievable.

An organic additive to an electrolyte for a battery cell in an implant able medical device is presented. At least one organic additive is selected from a group comprising one of lithium salivate, hydroxyphthalic anhydride, a hydroxybenzoic acid, salivate ester, salicylamide, and salicylanilide.

The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhea and C. difficile associated colitis.

The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or disorders associated therewith.

The invention belongs to the field of medical compounds and relates to a salicyloyl anilines compound as well as a preparation method and application in preparing an anti-cancer medicine. According to the method disclosed by the invention, the salicyloyl aniline is taken as a parent and different side-chain substituent groups are introduced into a benzene ring of the parent to prepare the salicyloyl anilines compound of the following formulas, wherein in the formulas, R1, R2, R3 and R4 are defined as an specification. Compared with the Lapatinib, the prepared salicyloyl anilines compound represents that the IC50 value is obviously reduced or is at least equal to that of the Lapatinib. The experiment shows that the salicyloyl anilines compound provided by the invention has an obvious inhibition effect on tumor cells, especially ovarian cancer cells so that the salicyloyl anilines compound can be further used for preparing antitumor medicines. The chemical formula of the salicyloyl anilines compound is represented by the following formulas.

The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-κB, and methods for treating diseases in which activation of NF-κB is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-κB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.

The present invention relates to non-aqueous topical compositions comprising a halogenated salicylanilide and the use of such compositions in the topical treatment or prevention of diseases and infections, particularly conditions caused by Gram-positive bacteria, for example the topical treatment or prevention of skin infections such as acne, atopic dermatitis and impetigo. Also disclosed are methods for preparing the gel composition.

The invention relates to cream shampoo for scalp itching relieving and a preparation method thereof. The cream shampoo comprises, by mass, the following components of 0.5-2.5 parts of olive oil, four to ten parts of stearic acid, four to 12 parts of glycerinum, 10-20 parts of laurinol polyoxyethylene ether sodium, one to four parts of glycol distearate, 0.5-1.2 parts of carboxymethylcellulose, 0.06-0.14 part of salicylanilide, 0.2-0.6 part of oleoyl sodium methyl taurate, 0.2-0.5 part of xanthan gum, two to seven parts of potassium hydroxide, 0.5-1.2 parts of selenium sulfide, 42-55 parts of water, 0.08-0.15 part of essence, 0.5 to two parts of borneol, 0.5 to two parts of rosin and 0.3 to one part of fructus kochiae. The cream shampoo can clean hair and the scalp effectively and fast, foam is exquisite and easy to wash off, and meanwhile the cream shampoo can effectively restrain itching caused by the dry scalp, and has the refreshing effect.

The invention provides new application of 4-hydroxy salicylanilide in the field of pharmacy. 4-hydroxy salicylanilide is an inhibitor of ribonucleotide reductase (RR) and inhibits the enzyme activity of RR, so that the compounding of dNTPs required by reproduction of HBV is blocked, and the aims of inhibiting reproduction of HBV, treating hepatitis and particularly treating hepatitis B are fulfilled. The 4-hydroxy salicylanilide can be used for preventing and treating the hepatitis B and has a significant application prospect.

The invention provides an antiviral compound preparation for fish. The compound preparation composition comprises microparticles containing macrolide anthelmintic, as well as two or more than two of bithionol, praziquantel, diflubenzuron, triflumuron, pyriproxyfen, sulfur powder, salicylanilide, organic phosphorus, benzimidazole, pyrethroid, triazine, tetramisole anthelmintic, sulfonamides, anticoccidial drugs and Chinese herbal medicine anthelmintic, wherein the microparticles containing macrolide anthelmintic are microspheres or microcapsules composed of biodegradable or non-biodegradable carrier materials and macrolide anthelmintic, and the content of the macrolide anthelmintic in the microparticles is 0.1-50%. The compound preparation provided by the invention can not only expand the insecticidal spectrum, but also effectively improve the anthelmintic activity and reduce toxicity so as to ensure safer use.

Provided is a method for exterminating parasites in fish in which a salicylanilide drug is administered to fish. The method for exterminating parasites is effective against parasites belonging to the class Monogenea or the class Trematoda. Oxyclozanide, rafoxanide, and closantel are preferred as the salicylanilide drug. The extermination agent is effective in fish belonging to the order Perciformes, the order Pleuronectiformes, the order Clupeiformes, the order Tetraodontiformes, the order Cypriniformes, the order Anguilliformes, and the order Siluriformes.

The invention discloses an antimicrobial pbt material. The antimicrobial pbt material is prepared from, by weight, 3-5 parts of polyvinylpyrrolidone, 70-80 parts of caprolactam, 10-13 parts of attapulgite, 1-1.4 parts of zinc acetate, 2-3 parts of gamma-aminopropyltriethoxysilane, 18-20 parts of oxalic acid, 300-370 parts of polybutylene terephthalate, 6-8 parts of octyl isothiazolinone, 1-2 parts of zinc sulfate, 1.7-2 parts of n-salicylanilide, 10-14 parts of butyl acrylate resin, 1-2 parts of bi-decyl dimethyl ammonium bromide, 0.7-1 part of nickel aminosulfonate and 2-3 parts of sodium diacetate. Polyvinylpyrrolidone, sodium diacetate and the like are further added to the material, and therefore the antimicrobial performance of the finished product is further improved.

Novel salicylic anilides are chemical uncouplers useful e.g. for the treatment of obesity.

The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.

The present invention is directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a salicylanilide or salicylanilide derivative, disclosed herein, alone or in combination with one or more other active or excipient pharmaceutical substances. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein, further comprised of one or more active or excipient pharmaceutical substances.

The invention discloses a wear-resisting elevator belt rubber material containing silicon. The wear-resisting elevator belt rubber material is characterized by comprising the following raw materials in percentage by weight: 25-35 parts of reinforced silicone rubber, 25-35 parts of styrene-butadiene rubber, 4-7 parts of zinc oxide, 5-8 parts of stearic acid, 0.6-0.8 part of an accelerant TMTD, 0.4-0.6 part of silicon dioxide hydrate, 0.3-0.5 part of an anti-aging agent, 2-4 parts of sulphur, 5-8 parts of acetylene black, 3-5 parts of pottery clay powder, 1-3 parts of salicylanilide, 0.7-0.9 part of bi-(3-triethoxypropyl-silane)-tetrasulfide, 0.8-1 part of a dispersing agent, 0.4-0.6 part of tetramethyl thiuram monosulfide and 0.4-0.6 part of an assistant. The obtained elevator belt rubber material has excellent heat resistance, heat-aging resistance, stretch resistance and wear-resisting property.

The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Gram positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

The invention discloses an environment-friendly, antibacterial and mouldproof rubber which comprises the following components in parts by weight: 20-50 parts of chloroprene rubber, 5-10 parts of smoked sheet 1# rubber, 10-15 parts of light calcium carbonate, 5-10 parts of salicylanilide, 1-5 parts of figuline powder, 20-30 parts of conductive carbon black, 1-2 parts of sodium tetraborate and 1-3 parts of paraffin oil. Compared with the prior art, the mouldproof rubber provided by the invention has the advantages that the mouldproof rubber is mainly made of chloroprene rubber and natural rubber, and since the natural rubber has good tensile strength and good electrical insulating property and is soft at a low temperature, the chloroprene rubber has the advantages of fire resistance, atmosphere corrosion resistance, mould prevention, heat resistance and the like, the mouldproof effect is greatly improved by addition of magnesium stearate, and the mechanical and physical properties are excellent.

An anti-parasiticidal composition presented as a topical “pour-on” product for treating animals infected by parasites which are known to be susceptible to salicylanilides, especially closantel, alone or together with at least one other anti parasitic compound of the avermectin or milbemycin type and offers enhanced bioavailability of the salicylanilide by provision of a delivery system comprising at least 20% (v / v) of one or more alcohols, and optionally including a polymeric moiety selected from the group consisting of polyvinylpyrrolidone (PVP), polyoxypropylene / polyoxyethylene block copolymers (poloxamer), and polyethylene glycols (PEG), thereby improving the bioavailability of e.g. closantel (as assessed with respect to blood plasma levels of closantel).

The present invention discloses aqueous micellar formulations for topical administration of benzimidazoles or salicylanilides with macrocyclic lactones to livestock for the control of endo- and ecto-parasites, comprising a first active agent selected from water insoluble benzimidazoles, salicylanilides and active derivatives or salts thereof, in combination with a second active agent selected from macrocyclic lactones or active derivatives or salts thereof, and also comprising, per litre of formulation: from about 100 to about 400 g veterinary acceptable surfactant(s); from about 200 to about 750 g veterinary acceptable water-miscible solvent(s); and from about 50 to about 350 g water, as well as methods for dosing livestock with such formulations, and methods for controlling and / or preventing diseases or parasite infection in livestock.

The invention discloses a hydrophobic whisker composite material which is prepared from the following raw materials in parts by weight: 0.7-2 parts of calcium ricinoleate, 100-130 parts of polypropylene, 24-30 parts of 3-(trifluoromethyl) benzophenone, 7-9 parts of hydroquinone, 10-13 parts of calcium carbonate whiskers, 0.4-1 part of potassium carbonate, 0.2-0.5 part of sodium carbonate, 100-120 parts of sulfolane, 0.5-1 part of 1H,1H,2H,2H-perfluorodecyl triethoxysilane, 2-3parts of hydroxystearicacid, 0.5-1 part of propylene glycol alginate, 6-8parts oftetrabutyl titanate, 0.8-1 part of aluminum ammonium sulfate, 0.6-1 part of 1,2-dimethylimidazole and 0.1-0.3 part of n-salicylanilide. The composite material has good hydrophobic property and excellent overall performance.

The invention discloses an anti-static cable sheath material. The anti-static cable sheath material is composed of, by weight, 2-4 parts of erucyl amide, 570-600 parts of polyvinyl chloride, 17-20 parts of fulvic acid, 0.06-0.1 part of sodium iodide, 40-50 parts of isopropyl alcohol, 70-100 parts of saponite, 2-3 parts of sp80, 20-30 parts of lactide, 0.2-0.25 part of L-arginine, 4-6 parts of polyving akohol, 1.6-2 parts of salicylanilide, 3-5 parts of sodium potassium silicate, 2-4 parts of 3-phenoxy-1-propanol, 10-18 parts of cresyl diphenyl phosphate and 2-4 parts of calcium palmitate. According to the cable sheath material, the components such as the erucyl amide and the salicylanilide are added, good anti-static property is achieved, the anti-static cable sheath material is suitable for protection of wires of electronic products such as household appliances and instruments, and the safety is high.

The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation preparation. The synchronisation preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation. The antibiotics include oral, injectable and implantable theurapeutic remedies. The vaccine includes antigens and a combination of antigens and adjuvents. The growth stimulants include zeranol, estradiol, testosterone, progesterone and trenbolone acetate. The dewormer includes macrocydic lactones, leramizoles, benzimidazoles and salicylanilides. The macrocydic lactones include doramectin, ivermectin, abamectin and moxidectin.

The invention discloses a preparation method for an antibacterial type rubber-plastic foaming thermal insulation material. The preparation method comprises the following steps: banburying chloroprene rubber, acrylonitrile-butadiene rubber and an ethylene-propylene methylene copolymer to a molten state at a temperature of 60-85 DEG C; adding phenolic resin, 4-aminophenethylalcohol, stearic acid and tributyl citrate, and mixing for 10-20 minutes at a temperature of 90-110 DEG C; when the temperature is reduced to 60-80 DEG C, adding carbohydrazide, calcium carbonate and normal hexane, and increasing the temperature to 100-120 DEG C; after reaching the temperature, continuously adding salicylanilide and active carbon supported with silver nitrate, continuously increasing the temperature to 160-200 DEG C, stirring and reacting for 20-40 minutes after keeping for 5-8 minutes, and cooling, cutting and drying, thereby obtaining the antibacterial type rubber-plastic foaming thermal insulation material. While antibacterial performances are improved, the heat conduction coefficient is further reduced, so that thermal insulation is better; and comprehensive properties of the material are improved through cooperation of rubber and plastic.

The invention relates to athletic sports facilities, in particular to a composite rubber health track. The track compounded from an upper layer and a lower layer, wherein the upper layer is a composite rubber layer, the lower layer is a regenerated rubber layer; the composite rubber layer is mainly made from butyl rubber, silicon rubber, natural rubber, ceramic clay, stearic acid, naphthenic oil, salicylanilide, sulfuretted rubber powder and phthalocyanine blue, and the thickness ratio of the composite rubber layer to the regenerated rubber layer is 1:0.8-1.2. Because the silicon rubber and fluorine rubber are added to the prescription, the track has favorable elasticity, intensity, toughness and damping effects, has the properties of wear resistance, dust prevention, inflaming retarding, static prevention, mildew proof, corrosion prevention, ultraviolet resistance, multivariant weather resistance without being affected by meteorological conditions, realizes the industrial large-scale production, can be installed and laid all over the world and be recycled and is green, environment friendly and safe.

The invention discloses a dyeing and finishing process of underwear fabric, which comprises the following steps: (1) pretreatment; (2) dyeing; (3) finishing: adding 1-2 parts by weight of gamma-(3-glycidoxypropyl) trimethoxysilane, 1.2 parts by weight of 4-Br-2-n-octylisothiazolinone, 0.9 part by weight of salicylanilide and 3.6 parts by weight of acrylic acid into 15 parts by mass of deionized water, and stirring uniformly; then adding 0.9 part by weight of bioresmethrin, 0.7 part by weight of isocyanuric acid triallyl ester, 0.9 part by weight of polyamide and 1.4 parts by weight of 3-(2-aminoethyl)-aminopropyl methyl dimethoxy silane, and continuously stirring till full and uniform mixing to prepare finishing liquid; then padding the fabric in the finishing liquid, taking out and drying at constant temperature.The fabric dyed and finished by the dyeing and finishing process has excellent mildewproof, mothproof, antibacterial, antiflaming and antistatic performances, and is high in washing resistance and soft in handfeel.